文献速递特殊人群用药药物不良反应与药物警戒

阿片类药物在孕产妇与儿科人群中的药理学研究现状与知识缺口

Pharmacotherapy research landscape and knowledge gaps of opioids in maternal and pediatric populations.
PubMed 文献 · Pharmacotherapy · 2025-05-15

本综述通过检索PubMed对27种阿片类药物在孕产妇与儿科人群中的药代动力学(PK)及药物流行病学(PE)或临床试验(CT)研究进行文献分析,并结合MarketScan理赔数据与FDA药品标签比较证据与处方现状。结果显示研究最集中的药物与处方最多的药物存在显著差异,孕产妇及高频处方药氢可酮、羟考酮的药理学知识缺口更大。

要点

  • 氢可酮、羟考酮和可待因处方最多,但PK与PE/CT研究集中在吗啡、芬太尼、美沙酮和丁丙诺啡。
  • 9种阿片类药物缺乏FDA标签,18种有标签药物中4种缺乏任何人体数据。
  • 孕产妇中7种药物缺乏PK和PE/CT研究,儿科中7种缺乏PK研究、8种缺乏PE/CT数据。

核心结论

  • 常用处方阿片类药物与研究证据之间存在显著差距,孕产妇及氢可酮、羟考酮的知识缺口尤为突出。
  • FDA标签中有限的人体数据强调需要开展更多研究,真实世界数据研究可能有助于填补这些缺口。

研究设计与样本

  • 本综述为阿片类药物在孕产妇与儿科人群中药理学知识缺口的现状分析。
  • 检索PubMed中27种阿片类药物的PK及PE或CT研究,纳入英文出版物并综合数据识别缺口。
  • 同时分析MarketScan理赔数据和FDA药品标签,比较科学证据、阿片类药物处方/订单与FDA推荐。

主要发现

  • 吗啡、芬太尼、美沙酮和丁丙诺啡是孕产妇与儿科人群中PK和PE/CT文献研究最多的阿片类药物。
  • 氢可酮、羟考酮和可待因是处方最多的阿片类药物。
  • 9种阿片类药物缺乏FDA标签,18种有标签药物中4种缺乏任何人体数据。
  • 氢可酮、羟考酮和可待因标签包含哺乳期PK信息,后两者有一些儿科临床数据。
  • 孕产妇中7种阿片类药物缺乏PK和PE/CT研究;儿科中7种缺乏PK研究、8种缺乏PE/CT数据。

关键数值与推荐

  • PK研究最常报告药物浓度,新生儿阿片戒断综合征(NOWS)是PK和PE研究的关键结局。
  • NOWS更多使用真实世界数据研究,神经发育结局常在前瞻性观察性研究中捕获。
  • 孕产妇PK研究常关注产程、分娩和哺乳并伴随新生儿数据,妊娠研究主要在PE研究中开展。
  • 儿科研究类型在儿童中分布均匀,但PE研究更侧重于青少年。

临床怎么用

  • 临床用药应关注高频处方药氢可酮和羟考酮在孕产妇与儿科人群中的证据缺口。
  • 参考FDA标签时需注意部分药物缺乏人体数据或标签缺失。
  • 可利用真实世界数据辅助评估NOWS等结局,并关注神经发育等长期结局。

局限性

  • 本综述未报告检索时限、纳入研究数量及偏倚风险评估等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use and misuse of opioids has surged in the past decade, with nearly half of the users being female. Although opioid use is lower among pregnant women, trends mirror the general population. While pediatric exposures largely occur through prescriptions. This review presents a novel landscape analysis of pharmacology knowledge gaps in opioids in the maternal and pediatric populations. We queried PubMed for studies on 27 opioids, focusing on pharmacokinetics (PK), and pharmacoepidemiology (PE) or clinical trials (CT) in maternal and pediatric populations. English-language publications were included, and data were synthesized to identify gaps. Additionally, MarketScan claims data and United States Food and Drug Administration (FDA) drug labels were analyzed to compare scientific evidence, opioid prescriptions/orders, and FDA recommendations. Morphine, fentanyl, methadone, and buprenorphine are the most researched opioids in PK and PE/CT literature in both populations, but hydrocodone, oxycodone, and codeine are the most prescribed. Nine opioids lack FDA labels, and four of the 18 labeled drugs lack any human data. Hydrocodone, oxycodone, and codeine labels include lactation-focused PK information, with some pediatric clinical data for the latter two. Seven opioids lack PK and PE/CT studies in the maternal population, and PK research is absent for seven opioids, and PE/CT data is lacking for eight opioids in the pediatric population. PK studies often focus on labor, delivery, and lactation accompanied by neonatal data, whereas pregnancy research mainly occurs in PE studies. In pediatric populations, study types are evenly distributed among children, but PE studies focus more on adolescents. Drug concentration is the most reported parameter in PK studies, and neonatal opioid withdrawal syndrome (NOWS) is a key outcome in both PK and PE studies. NOWS is also researched more using real-world data, whereas neurodevelopmental outcomes are often captured in prospective observational studies. There is substantial disparity between the most commonly researched and prescribed opioids. In particular, the opioid pharmacology knowledge gaps are larger in pregnant women and for the highly prescribed opioids hydrocodone and oxycodone. The limited human data in FDA labels underscores the need for additional studies. Studies using real-world data can potentially help address these gaps.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Shendre A, Liu X, Chiang C, et al. Pharmacotherapy research landscape and knowledge gaps of opioids in maternal and pediatric populations. Pharmacotherapy. 2025. PMID: 40371673. doi:10.1002/phar.70024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。